Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study

Pedersini, Rebecca; Vassalli, Lucia; Claps, Mélanie; Tulla, Antonella; Rodella, Filippo; Grisanti, Salvatore; Amoroso, Vito; Roca, Elisa; Simoncini, Edda; Berruti, Alfredo

doi:10.1159/000489063

Cited by 22 publications

(25 citation statements)

References 30 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the results of our study are comparable with those previously reported. Median PFS (134 days, approximately 4.5 months) was comparable with that reported for previous clinical studies (range: approximately 3–5.1 months) [ 15 , 16 , 20 , 24 , 25 ]. We also report a slightly longer median OS (631 days, approximately 21 months) than previous studies (range: 8.8–15.9 months) [ 15 , 16 , 20 , 24 , 25 ].…”

Section: Discussionsupporting

confidence: 86%

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)

Park

Lee

Noh³

et al. 2020

The Breast

View full text Add to dashboard Cite

Purpose Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study. Methods Patients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m 2 (equivalent to 1.4 mg/m 2 eribulin mesylate) by intravenous infusion for 2–5 min, or as a diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent adverse events (TEAEs). Results The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common. Conclusion Real-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified.

show abstract

Section: Discussionsupporting

confidence: 86%

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)

Park

Lee

Noh³

et al. 2020

The Breast

View full text Add to dashboard Cite

show abstract

“…Eribulin has anticancer effect against a wide range of cancers (lung, bladder, cervical, esophageal, and head and neck cancer) and overall survival has shown to be significantly improved in locally advanced or metastatic breast cancer . Eribulin is administered intravenously with a dose of 1.4 mg/m 2 on days 1 and 8 of a 21‐day cycle, metabolized mainly by hepatic CYP3A4 enzyme and excreted unchanged mostly through liver and urine. Therefore, dose reduction is required in hepatic and/or renal impairment (up to 0.7 mg/m 2 ).…”

Section: Oncological Use Dose and Neurotoxicitymentioning

confidence: 99%

“…Its analogue, lenalidomide is also routinely used in hematological malignancies. Eribulin is a synthetic analogue of halichondrin B produced by the marine sponge Halichondria okadai and a relatively newer anticancer agent providing promising anticancer effect in metastatic breast cancer …”

Section: Introductionmentioning

confidence: 99%

Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

Islam

Lustberg

Staff

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Vinca alkaloids, thalidomide, and eribulin are widely used to treat patients with childhood acute lymphoblastic leukemia (ALL), adults affected by multiple myeloma and locally invasive or metastatic breast cancer, respectively. However, soon after their introduction into clinical practice, chemotherapy-induced peripheral neurotoxicity (CIPN) emerged as their main non-hematological and among dose-limiting adverse events. It is generally perceived that vinca alkaloids and the antiangiogenic agent thalidomide are more neurotoxic, compared to eribulin. The exposure to these chemotherapeutic agents is associated with an axonal, length-dependent, sensory polyneuropathy of mild to moderate severity, whereas it is considered that the peripheral nerve damage, unless severe, usually resolves soon after treatment discontinuation. Advanced age, high initial and prolonged dosing, coadministration of other neurotoxic chemotherapeutic agents and pre-existing neuropathy are the common risk factors. Pharmacogenetic biomarkers might be used to define patients at increased susceptibility of CIPN. Currently, there is no established therapy for CIPN prevention or treatment; symptomatic treatment for neuropathic pain and dose reduction or withdrawal in severe cases is considered, at the cost of reduced cancer therapeutic efficacy. This review critically examines the pathogenesis, epidemiology, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of CIPN as a result of exposure to vinca alkaloids, thalidomide and its analogue lenalidomide as also eribulin. K E Y W O R D S assessment, eribulin, peripheral neurotoxicity, thalidomide, vinca alkaloids

show abstract

“…Eribulin is already being used successfully in community settings around the world, including the United States [52,53], Italy [56,70,71], and Japan [58,60,61]. Depending upon the region, eribulin is currently considered a second-or third-line therapy in patients with MBC.…”

Section: Expert Opinionmentioning

confidence: 99%

The safety of eribulin for the treatment of metastatic breast cancer

Peréz-García

Cortés

2019

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction: Eribulin mesylate is a highly potent anticancer agent approved for use in pretreated metastatic breast cancer (MBC). Clinical trials of eribulin in MBC have demonstrated activity against this tumor type, and a phase 3 study in patients with MBC previously treated with an anthracycline and a taxane showed a significant increase in overall survival (OS) with eribulin versus control regimens. Areas covered: This review presents overviews of the development of eribulin, its pharmacology, and its efficacy in MBC. A detailed review of its safety profile is presented, and the safety of eribulin is compared with other agents commonly used to treat MBC. Expert opinion: As eribulin is the only drug shown to improve OS in patients with pretreated MBC, it is an important treatment option for many patients. Eribulin is currently considered a second-line (Europe) or third-line (United States) therapy, and studies have been examining use in the first-line setting. The use of eribulin in combination with other therapies is beginning to be explored because its manageable safety profile makes it an ideal combination-treatment partner. Emerging eribulin combinationtreatment data suggest a manageable toxicity profile, and eribulin is set to be a key drug for the treatment of MBC in the future.

show abstract

Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study

Cited by 22 publications

References 30 publications

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)

Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

The safety of eribulin for the treatment of metastatic breast cancer

Contact Info

Product

Resources

About